Cell Therapy Worldwide: An Incipient Revolution
Authors:
- 1 March 2015
- journal article
- review article
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 10 (2) , 181-191
Abstract
The regenerative medicine field is large, diverse and active worldwide. A variety of different organizational and product models have been successful, and pioneering entrepreneurs have shown both what can work and, critically, what does not. Evolving regulations, novel funding mechanisms combined with new technological breakthroughs are keeping the field in a state of flux. The field struggles to cope with the lack of infrastructure and investment, it nevertheless has evolved from its roots in human stem cell therapy and tissue and organ transplants to a field composed of a variety of products from multiple cell sources with approval for use in numerous countries. Currently, tens of thousands of patients have been treated with some kind of cell therapy.Keywords
Funding Information
- NYSCF
- NYSCF
- NYSCF
- NYSCF
This publication has 64 references indexed in Scilit:
- Does the FDA have regulatory authority over adult autologous stem cell therapies? 21 CFR 1271 and the emperor's new clothesJournal of Translational Medicine, 2012
- Cell-Based Therapy for Neural Disorders — Anticipating ChallengesNeurotherapeutics, 2011
- Regenerative medicine. Opportunities and challenges: a brief overviewJournal of The Royal Society Interface, 2010
- Stem cell‐based cell therapy in neurological diseases: A reviewJournal of Neuroscience Research, 2009
- Adoptive cell transfer: a clinical path to effective cancer immunotherapyNature Reviews Cancer, 2008
- Mesenchymal Stem Cells: Revisiting History, Concepts, and AssaysCell Stem Cell, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for HomingStem Cells, 2007
- Embryonic Stem Cell Lines Derived from Human BlastocystsScience, 1998
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988